Texas Heart Institute and BiVACOR achieve milestone with total artificial heart implantation

The Texas Heart Institute (THI) and BiVACOR, a clinical-stage medical device company, announced today the successful first-in-human implantation of the BiVACOR Total Artificial Heart (TAH) as part of the U.S. Food and Drug Administration (FDA) Early Feasibility Study (EFS) on July 9, 2024.

A novel approach to IV access

Editor’s note: Joseph Smith is chief scientific officer of BD, which makes instrument systems and medical devices, including equipment for vascular access management. Views are

Read More »